GLP-1 Medicines and Mental Health: What the Evidence Actually Says

Questions about GLP-1 medicines and mental health travel fast online. Some people describe feeling calmer around food; others talk about anxiety, low mood or simply feeling different as their appetite changes. Personal reports deserve respect, but they can't tell us how often something happens or whether a medicine caused it. Mood is shaped by many things at once—biology, sleep, stress, relationships, money and life events.

What did the FDA conclude about suicidal thoughts?

On 13 January 2026, the US FDA said its review found no increased risk of suicidal thoughts or behavior with GLP-1 receptor agonist medicines, and asked for that warning to be removed from the labels of Wegovy, Zepbound and Saxenda (medicines approved only for type 2 diabetes, like Ozempic and Mounjaro, never carried it). The Wegovy and Zepbound labels show the warning removed in February 2026.

The FDA based this on several lines of evidence, including:

• a meta-analysis of 91 placebo-controlled trials with 107,910 participants, which found no increased risk of suicidal thoughts or behavior—or of related psychiatric events such as anxiety, depression, irritability or psychosis;
• a large FDA Sentinel study of about 2.24 million new users, which found no increased risk of intentional self-harm with GLP-1 medicines compared with another diabetes medicine class (SGLT2 inhibitors).

A reassuring population-level finding doesn't mean you should ignore your own symptoms. The FDA still advises telling a healthcare professional about new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.

Why can people's experiences differ?

Changes in appetite, weight, routines, social life, side effects, sleep, costs and expectations can all affect how treatment feels. In a 2026 JAMA Network Open interview study of 30 US adults (90% had type 2 diabetes), participants described reduced "food noise," a wide range of side effects, stigma, access and cost struggles, and very uneven support from clinicians. Some described food as their old way of coping with boredom or sadness and said that pull had quieted.

Interview studies like this show the range and meaning of experiences; they don't measure depression or anxiety, and they can't give population percentages. One person's brighter mood or difficult month isn't a universal medication effect. If food and feelings are tangled up for you, our piece on GLP-1 medicines and emotional eating goes deeper.

What if your mood changes after starting treatment?

Tell a healthcare professional about new or worsening depression, anxiety, agitation, sleep changes or distress. Share when it began and what else changed around that time. If you have thoughts of harming yourself or feel unable to stay safe, seek help immediately: in the US, call or text 988 (Suicide & Crisis Lifeline), or contact local emergency services wherever you are. Don't wait for a routine follow-up.

How to read online claims

Be cautious with posts claiming GLP-1 medicines are proven antidepressants, that they inevitably cause depression, or that they cure addictions. Research into the brain's reward pathways is ongoing (for example, on alcohol cravings), and results differ by outcome and study design. A trustworthy source will label which findings are hypotheses, which are observational, which come from randomized trials and which are approved uses.

A balanced conversation can honor personal experience without turning it into proof. Your mental wellbeing matters, and treatment decisions should consider the whole person—not just the number on a scale.